Scientific Committee

United States

Scientific Committee

United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 18, 2017
Site: www.prweb.com

Worldwide, diabetes affects around 415 million adults, a number estimated to rise to 642 million by 2040 (1 in 10 adults), with 50% of deaths in people with T2D caused by cardiovascular disease. Specifically, people with type-2 diabetes (T2D) face a much higher risk of heart failure and death than those without diabetes. The prognosis for patients with diabetes that develop heart failure is especially ominous. However, research led by Mikhail Kosiborod, M.D. at Saint Luke’s Mid America Heart Institute, in coordination with the CVD-REAL Executive Scientific Committee, and published today in the American Heart Association’s flagship journal, Circulation, revealed that patients treated with sodium-glucose co-transporter-2 inhibitor (SGLT-2i) medicines experienced a significantly lower risk of hospitalizations for heart failure and death when compared with T2D patients treated with other glucose lowering drugs (oGLDs). The CVD-REAL study assessed data from more than 300,000 patients across six countries, 87% of whom did not have a known history of cardiovascular disease. The data showed that across this broad population of patients with T2D, treatment with SGLT-2i medicines - canagliflozin, dapagliflozin and empagliflozin - was associated with a 39% lower risk of hospitalization for heart failure (HR 0.61; 95% CI 0.51-0.73; p<0.001) and 51% lower risk of death from any cause (HR 0.49; 95% CI 0.41-0.57; p<0.001), compared with other T2D medicines. For the composite endpoint of hospitalization for heart failure or death from any cause, treatment with SGLT-2i versus other drugs was associated with a 46% lower risk (HR 0.54; 95% CI 0.48-0.60; p<0.001). “T2D remains a major risk factor for cardiovascular disease and overall mortality despite advances in treatment,” said Saint Luke’s cardiologist Mikhail Kosiborod, M.D., the lead author of the study. “There is a substantial need to develop treatments that not only lower blood glucose levels, but also reduce the risk of cardiovascular complications, including heart failure. The CVD-REAL study results suggest that SGLT-2i medicines may have a significant impact on reducing those risks and may improve overall outcomes in a much broader population of patients with T2D than previously thought.” The hospitalizations for heart failure analysis was conducted using anonymized patient data from Denmark, Norway, Sweden, United Kingdom, Germany and the United States. Of the data reviewed, 53% were on canagliflozin, 42% on dapagliflozin, and 5% on empagliflozin. The analysis of death from any cause was conducted using anonymized patient data from Denmark, Norway, Sweden, United Kingdom and the United States. Of the data reviewed, 42% of patients were on canagliflozin, 51% on dapagliflozin and 7% on empagliflozin. Among patients treated with SGLT-2i, the majority in the US received canagliflozin, and the majority in Europe received dapagliflozin; lower risks of hospitalization for heart failure and death associated with SGLT-2i use were seen both in the US and Europe, suggesting that these potential benefits may represent a class effect. This is the first of several comparative analyses of CVD-REAL. The study is ongoing and future analyses will be conducted using this dataset as well as data from additional countries. The data for this study were obtained from real-world sources including medical records, claims databases and national registers, and were not independently adjudicated or verified against source documents. The CVD-REAL study is sponsored by AstraZeneca. This study was validated by the independent academic statistical group at St. Luke’s Mid America Heart Institute, Kansas City, US. While CVD-REAL is a large study with a robust propensity-matching technique, given its observational nature the possibility of residual, unmeasured confounding factors cannot be definitively excluded. Saint Luke’s Mid America Heart Institute is a member of Saint Luke’s Health System, which consists of 10 area hospitals and several primary and specialty care practices, and provides a range of inpatient, outpatient, and home care services. Founded as a faith-based, not-for-profit organization, our mission includes a commitment to the highest levels of excellence in health care and the advancement of medical research and education. The health system is an aligned organization in which the physicians and hospitals assume responsibility for enhancing the physical, mental, and spiritual health of people in the metropolitan Kansas City area and the surrounding region.


News Article | May 19, 2017
Site: cerncourier.com

One of the most brilliant theorists of his time, Pierre Binétruy, passed away on 1 April. Binétruy received his doctorate on gauge theories in 1980 under the direction of Mary K Gaillard, and held several positions including a CERN fellowship and postdocs in the US. In 1986, he was recruited as a researcher at LAPP in Annecy-le-Vieux and, four years later, he moved to the University of Paris XI. Since 2003 he was a professor at Paris Diderot University. He helped to found the Astroparticle and Cosmology Laboratory (APC) in 2005 and was its director until 2013. We also owe to him the involvement of the APC in space sciences, Earth sciences, and the realisation of the importance of data science. Binétruy’s research interests evolved from high-energy physics (notably supersymmetry) to cosmology and gravitation, and in particular the intersection between the primordial universe and fundamental theories. His recent interests included inflation models, dark energy and gravitational-wave cosmological backgrounds. During his prolific career, he published seminal papers that approached 1000 citations each and received several awards, including the Thibaud Prize and the Paul Langevin Award. But he will also be remembered for his spirit and courage. He knew that it was necessary not only to seek scientific truth but also to have the courage to prepare the community for the scientific goals that this truth demands and to fight to defend them. Older members of IN2P3 remember the extraordinary intellectual atmosphere that animated the Supersymmetry Research Group, which he proposed and directed from 1997 to 2004, transforming it into an unprecedented crossroads for experimenters and theorists. By that time, when the detection of gravitational waves was for many a distant dream, he also had the intuition to involve France in the field of gravitational-wave detection via the LISA Pathfinder programme – a scientific choice to which he devoted great dynamism right up to his death. Binétruy was also an inspiration to hundreds of students. Through the MOOC Gravity project, which he developed in collaboration with George Smoot, his courses reached tens of thousands of students. He viewed MOOC not just as a simple way to improve the visibility of the university, but as a revolution in the way knowledge is diffused. In parallel with these activities, Binétruy found time to be president of the Fundamental Physics Advisory Group (2008–2010) and the Fundamental Physics Roadmap Committee (2009–2010) of ESA; the French consortium of the LISA space mission; the theory division of the French Physical Society (1995–2003); and the theory section of CNRS (2005–2008). He was also a member of the IN2P3 Scientific Committee (1996–2000) and numerous other panels. Alongside his scientific activities, which he pursued with enthusiasm and unfailing rigor, Binétruy had a deep appreciation and knowledge of broader culture. He had a profound knowledge of the arts, where he was the driving force behind several interactions between art and science. As one of his eminent colleagues said of him: “Pierre was one of those very exceptional people who was at the top of the game and, at the same time, a remarkably pleasant colleague.” Our mentor, colleague and close friend Gösta Ekspong passed away peacefully on 24 February at the age of 95. His life as a particle physicist covered the nuclear-emulsion epoch, the bubble-chamber years, experiments at CERN’s Large Electron–Positron (LEP) and Super Proton Synchrotron colliders. In his retirement he closely followed the results from the LHC, in particular the search for the Higgs boson. In 1950 Ekspong was working with Cecil Powell’s group in Bristol, UK, which had become a world-leading centre for cosmic-ray emulsion work. In a brilliant experiment with Hooper and King he identified the decay π0 → γγ. By observing e+e– pairs from the conversion of the photons close to cosmic-ray interactions, it was possible to determine the mass of the π0 and set an upper limit for its lifetime. Ekspong obtained his doctorate at Uppsala University, Sweden, in 1955, and immediately took up a postdoc position in Emilio Segré’s group at Berkeley where he was involved in the discovery of the antiproton at the Bevatron. Scanning emulsions one evening, he found the first evidence for an annihilation interaction in an emulsion, and on the 50th anniversary of the discovery of the antiproton he was invited to Berkeley to talk about the discovery. Ekspong was appointed to the first chair in particle physics in Sweden, at Stockholm University, in 1960. There he founded a large particle-physics group that over the years made important contributions to many experiments with data mostly from CERN. He strongly supported the use of CERN, where he was a member and chair of the Emulsion Committee in the early 1960s and a member of the Scientific Policy Committee from 1969 to 1975. He was Swedish delegate to CERN Council for many years and was a catalyst for the development of Swedish particle physics. He was elected to the Royal Swedish Academy of Sciences in 1969 and was a member of its Nobel Committee for physics from 1975 to 1988, chairing the committee from 1987 to 1988. His deep knowledge of statistics allowed Ekspong to clarify general features of high-energy interactions. Data from CERN’s Proton Synchrotron and bubble chambers had suggested that the multiplicity distributions of charged particles obeyed so-called “KNO” scaling, but this relationship was found not to be valid in later collider data recorded at higher energies with the UA5 experiment. In a discovery reported and discussed by him at many conferences, Ekspong showed that the distributions instead followed a negative binomial distribution. In the early studies of physics possibilities at the planned LEP collider, Ekspong also made a convincing contribution to the search strategy for observing the Higgs boson by carefully examining the experimental mass resolution. This strategy was later employed by the LEP experiments to exclude the Higgs mass up to about 115 GeV. He also took part in the technical development of one of the LEP experiments, DELPHI. Gösta Ekspong inspired many with his lectures, discussions, and stories about Nobel-prize discoveries. In many articles in Swedish he made physics available and understandable for the general public. Gareth Hughes joined the high-energy physics group at Lancaster University in 1970, following his undergraduate and postgraduate studies at Oxford University. He was born in Wales and was a proud supporter of the Welsh Rugby Union team, although he had never played the game. He used to say that he was among the few Welshmen who never played rugby, who could not sing and who did not like leeks. Ironically, he died on the feast day of St David, the patron saint of Wales. Following his appointment in Lancaster, Gareth played a central role in the work of the Manchester–Lancaster experiment (dubbed “Mancaster”) at Daresbury Laboratory to study the electro-production of nucleon resonances (by which the components of the nucleon are converted to more highly energetic states). He subsequently went on to work on the JADE experiment at DESY, the ALEPH and then ATLAS experiments at CERN – all of which have been key in establishing the Standard Model of particle physics. Gareth’s main strength was computing. In the 1990s, as well as being a member of the CERN Central Computing Committee, he was chairman of the committee that produced the policy on computing for UK particle physics. This was a very rapidly changing field at the time but a subject in which Gareth’s insight and guidance was to prove invaluable. He was also a prominent member of the Particle Physics Grants Committee and other bodies that manage funding for UK particle physics. He was an excellent teacher, his gentle sense of humour and infinite patience making him a much sought after member of staff by both undergraduate and postgraduate students. He eventually became director of undergraduate courses within the physics department at Lancaster. Gareth’s quick grasp of a situation and clear insight made him an extremely valuable colleague with whom to discuss problems. He was widely known and, in turn, seemed to know everyone. This proved to be a great help on numerous occasions. He retired from the physics department in 2007 but continued his involvement with the ATLAS experiment as an emeritus staff member until his death following a short illness. He will be sorely missed by us all but especially by his wife Jane, daughter Siân and son Owain, and his four grandchildren. Thomas Massam received his undergraduate degree in physics in 1956 at the Chadwick Laboratory, Cambridge, and his PhD at the University of Liverpool in 1960. Jovial but very serious and tireless at work, Tom devoted his life to experimental-physics research and to his family. I had the privilege of meeting Tom at the Fermi Summer School of Physics in Varenna, Italy, in 1962. The topics discussed at the school were the results of the Blackett group on the unexpected V particles, later called “strange” by Gell-Mann, and the effects of “virtual physics” in properties of the elementary particles and the experimental-plus-theoretical research needed. Tom was the most active student of the school, and soon afterwards he joined my group at Bologna University and remained there until his retirement in 2002. Together we performed experiments in all of the important laboratories in Europe, including CERN, DESY, ADONE and Gran Sasso. Tom had an extraordinary intelligence, work capacity and “scientific fidelity”. He is also one of the founders of the Ettore Majorana International Centre for Scientific Culture, established at CERN in the early 1960s with its headquarters in Erice, Sicily. In 1972, Tom initiated an International School of Theory Application of Computers. Tom played a major role, contributing with his extraordinary experimental talents, in experiments that established evidence for the Standard Model during the 1960s and afterwards. He helped to set up the first large-scale non-bubble-chamber facility at CERN, and was a close collaborator in our adoption of electromagnetic calorimeters as a tool to separate leptons from hadrons to allow searches for new particle states. Together, we started the first heavy-lepton search and developed a new technology to measure the time-of-flight of particles with a very high precision, leading to the first experimental observation of anti-deuteron production. Tom, research director in the INFN unit of Bologna, was also giving regular physics courses to the students at the ISSP International School of Subnuclear Physics in Erice, established in 1963. Tom is no longer with us. On 1 December 2016 he left his beloved family, Veronica with three children Peter, Steven, Paul, and his friends and colleagues with the unforgettable memory of his extraordinary life. Arthur H Rosenfeld, a long-time member of the faculty at the University of California, Berkeley, and distinguished senior scientist at the Lawrence Berkeley National Laboratory, passed away in Berkeley on 27 January at the age of 90. A student of Enrico Fermi, he was a leading participant in the revolutionary advances in particle physics in the 1950s and 1960s before striking out in a new direction, where he became legendary. A fitting tribute to Art was the award in 2006 of the Enrico Fermi Award of the US Department of Energy “for a lifetime of achievements ranging from pioneering scientific discoveries in experimental nuclear and particle physics to innovations in science, technology, and public policy for energy conservation that continue to benefit humanity. His vision not only underpins national policy but has helped launch an industry in energy efficiency”. Art’s first impact on the physics community was with Jay Orear and Robert Schluter, when the three of them produced the book Nuclear Physics consisting of the notes from Fermi’s course at the University of Chicago. Art came to Berkeley from Chicago and was part of Luis Alvarez’s team, which used bubble chambers to discover many of the meson and baryon resonances, including the omega meson and the Σ*(1385), which led to the recognition of SU(3) flavour symmetry. Art co-authored papers not only with experimenters, but also with Murray Gell-Mann, Shelly Glashow, and Sam Treiman. The 1957 Annual Review of Nuclear Science paper with Gell-Mann, “Hyperons and Heavy Mesons (Systematics and Decay)”, was the beginning of the Particle Data Group. Today’s Particle Data Group and the Review of Particle Physics are, 60 years later, Art’s legacy to the physics community. Much greater still is Art’s legacy to the US and international communities, which benefit today from his relentless pursuit of increased efficiency in the use of energy through both technological advances and political advocacy. The oil embargo of 1973 led Art to wonder why he saw so many obviously wasteful practices in the use of energy. He devoted the rest of his career to rectifying this. That per-capita usage of energy in California remained essentially constant from 1973 to 2006, while it rose by 50% elsewhere in the US, was given the name “The Rosenfeld Effect,” because of Art’s success in getting the state to adopt policies encouraging efficient use of energy. Art, together with a number of nuclear and particle physicists, and with the backing of Andrew Sessler, the director of the Lawrence Berkeley Laboratory in the mid-1970s, developed programmes in energy efficiency for buildings, appliances and lighting, which became a major part of the Laboratory’s programme. Art’s efforts extended beyond the laboratory. He was a founder of the American Council for an Energy-Efficient Economy, a non-profit organisation that continues today to push for policies that increase energy efficiency. Art served in the Clinton administration from 1994 to 1999 as senior adviser to the DOE’s assistant secretary for energy efficiency and renewable energy, and subsequently as commissioner at the California Energy Commission under two state administrations. Among the numerous honours Art received was the National Medal of Science and of Technology and Innovation presented by president Barack Obama in 2011 for “extraordinary leadership in the development of energy-efficient building technologies and related standards and policies”. Art showed that the analytical skills and pragmatism the physics community values could be put to use on practical problems facing humanity. The result of his dedication was profound and lasting contributions to energy efficiency. Despite Art’s ever growing fame, he remained an unassuming colleague, and we remember him as a friend whose achievements transcended the scope of our ordinary research endeavours. Durga Prasad Roy, or DP as he was popularly known, passed away on 17 March in Cuttack, India, after a brief illness. He was active until his last days, having posted a review on the arXiv preprint server in August 2016, participated in conferences in 2017 and having given a series of lectures on the Standard Model at the University of Hyderabad just a few days before he fell ill. DP completed his PhD in particle physics in 1966 at the Tata Institute of Fundamental Research (TIFR), Mumbai, and was a postdoctoral fellow at the University of California (1966–1968), CERN (1968–1969) and the University of Toronto (1969–1970). He moved to the Rutherford Laboratory in the UK (1970–1974), and was a reader at Visva Bharati University, India, from 1974 to 1976. He joined TIFR in 1976 and retired 30 years later in 2006. He then became a member of the Homi Bhabha Centre of Science Education. Scientifically, DP had an instinct for recognising what is important. He made pioneering contributions in particle- and astroparticle-physics phenomenology. His early research work was in the area of “Regge phenomenology and duality”, which addresses the dominant part of cross-sections for hadron–hadron collision processes. Using these ideas, DP predicted exotic mesons called baryonium (now termed tetraquarks) as well as exotic pentaquark baryons – robust predictions that continue to attract the attention of experimentalists and lattice-QCD experts. Along with his collaborators, he suggested to look for a hard isolated lepton and jets as a signature of the top quark, a methodology widely adopted at the CERN and Tevatron proton–antiproton colliders. He also worked extensively on many popular theories of physics beyond the Standard Model, such as supersymmetry. He suggested a promising signature with which to search for charged Higgs bosons using tau decays and the distinctive polarisation of these particles, which is currently being used in the ongoing search for charged Higgs boson at the LHC. Likewise, the missing transverse-momentum signature for supersymmetric particles suggested by DP is being widely used in the ongoing collider searches for these particles. DP and collaborators, and other groups, employed global fits of the solar-neutrino data, including the SNO neutral-current data from 2002, to pin down the large-mixing-angle (LMA) Mikheyev–Smiron–Wolfenstein (MSW) solution to the solar-neutrino problem. This was tested by two impressive sets of neutrino-spectrum results published by the KamLAND experiment in 2003 and 2004. Incorporating these data further in their analysis, and focussing on the LMA–MSW solution in the two-neutrino framework, DP and collaborators ruled out the high-mass-squared-difference LMA solution by more than three standard deviations and converged on the low-mass-squared difference LMA as the unique solution. His scientific achievements were recognised by the Meghnad Saha Award and the SN Bose Medal. He was elected fellow of the Indian Academy of Sciences, Indian National Science Academy and National Academy of Sciences. Along with his colleague Probir Roy, DP started a series of workshops in high-energy physics phenomenology called WHEPP that still initiate a lot of collaborative work today. He was passionate about undergraduate teaching, but also had many interests outside science. He was a weightlifting champion of Orissa, an expert swimmer, and a connoisseur of Indian classical music and dance. His passion for adventure always showed up in the after-work evening activities at WHEPP workshops. He also had strong views on the lack of experimental investigations in ancient India, and published them in an article in the Indian Journal of History of Science in 2016.


News Article | May 9, 2017
Site: www.prweb.com

Star Refrigeration’s Group Managing Director Dr Andy Pearson will deliver an insightful industry paper to raise awareness of natural refrigerants and new innovative components for industrial systems. The paper, which aims to forecast the industry’s future, analyses past and current events to reveal the “Megatrends” set to drive the industrial refrigeration sector forward. Dr Pearson, who is President of Scientific Committee, Former President of IoR UK and a Member of IIR Commission E1 said, “There are many external factors which will influence the design of refrigeration systems in the next twenty five years. Sharing, discussing and examining these at high profile events such as the IIR Conference is important to ensure we are prepared for these trends”. Pearson’s paper is titled ‘Megatrends in Industrial Refrigeration’ and covers various external factors that are likely to influence the decisions taken by designers of industrial refrigeration systems and examines them in different contexts. Carbon reduction, automation, globalisation and universality, as in the rapid transfer and sharing of information and knowledge, are considered in the light of increased urbanisation, growing environmental awareness and ever-present pressure on cost. The International Institute of Refrigeration hosts a global conference each year. It currently has 58 member countries and organises events all over the world promoting the sharing of knowledge of refrigeration and related technologies. This paper is just one of many included in the conference programme to be delivered by Star Refrigeration staff. Delegates will hear another keynote speech from Dr Rob Lamb, Star Refrigeration Group Sales and Marketing Director who will provide an overview of low charge ammonia refrigeration systems looking at the multiple factors driving the transition to greener, cleaner and more efficient cooling solutions. Star’s consultancy company, Star Technical Solutions will also be represented with Dr Dermot Cotter sharing its specialised engineering knowledge on ammonia refrigeration systems safety and legislative compliance. The International Institute of Refrigeration conference runs from 11th – 13th May 2017 in Ohrid, Republic of Macedonia. To find out more about the event and how to register go to: https://www.mf.edu.mk/web_ohrid2017/ohrid-2017.html To find out more about Star Refrigeration and its pioneering work in the development of refrigeration systems, visit the website at http://www.star-ref.co.uk


ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a widely recognised practical resource developed to guide healthcare professionals and policy makers, and represents the latest clinical evidence and medical practice for the treatment and management of asthma. The strategy is updated annually based on review of recent scientific literature by an international panel of experts on the GINA Science Committee. The 2017 update, which includes new information regarding the use of allergy immunotherapy, has just been released and features the following addition to steps 3 and 4 of GINA’s recommended stepwise treatment of asthma in adult house dust mite (HDM) sensitive patients: Consider adding SLIT (sublingual allergy immunotherapy) in adult HDM sensitive patients with allergic rhinitis who have exacerbations despite ICS (inhaled corticosteroids), provided FEV1 is > 70% of predicted lung function.1) This change draws upon recently published results from ALK’s Phase III clinical trial evaluating the treatment of HDM allergic asthma with the HDM SLIT-tablet, ACARIZAX® in The Journal of the American Medical Association (JAMA).2) Henrik Jacobi, Executive Vice President of Research & Development at ALK, said: “We are extremely pleased to see the recognition of ACARIZAX® clinical evidence in the management of asthma. This confirms our long-held conviction that allergy immunotherapy has an important role to play in the treatment of allergic asthma, a belief confirmed by the unprecedented clinical development programme for ACARIZAX®, currently the only HDM SLIT-tablet indicated for use in patients with house dust mite allergic asthma that is not well controlled.” House dust mite allergy and asthma often coexist. More than half of asthmatic patients have been reported to have house dust mite sensitisation. He continued: “ALK is committed to gathering further evidence to support the wider recognition of allergy immunotherapy as a treatment option for asthma, and to investigating the potential role for allergy immunotherapy in preventing the onset of asthma.” Professor J. Christian Virchow, of the University of Rostock and lead author of the recently published paper in JAMA says: “This is very encouraging. I am pleased to see findings from this important trial translated into clinical guidelines. This underlines the importance of performing robust evidence based trials in allergy immunotherapy.” ACARIZAX® is currently approved for the treatment in HDM allergic asthma in 12 European countries and Australia. For further information please contact: Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014 Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 About ALK ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net. About house dust mite allergy and ACARIZAX®   House dust mites (HDM) are the most common cause of allergy in the world. HDM allergy is estimated to affect around 90 million people in Europe, North America and Japan, and more than 100 million in China. It is estimated that one in 10 adults with allergic rhinitis are poorly controlled with current standard therapies. The condition appears early in life, is present all year round and patients face an elevated risk of developing asthma and other allergies. For some of these patients, the HDM SLIT-tablet is a relevant treatment option which can improve their quality of life and potentially modify the underlying cause of their disease. ALK’s HDM SLIT-tablet is a treatment for house dust mite-induced allergic rhinitis (AR) with or without conjunctivitis and allergic asthma (AA) that is not well controlled by symptomatic medication. In Europe, where it is marketed as ACARIZAX®, the product has been approved in 14 countries for the treatment of AR, 12 of which also include the HDM AA indication. It is also approved in Japan for AR, where it is licensed by ALK to Torii and marketed under the trade name MITICURETM and in Australia for HDM AR and AA, where it is licensed by ALK to Seqirus. The product is also being developed for a number of other markets around the world, including China, North America and countries in Southeast Asia. Altogether, clinical development activities for the HDM SLIT-tablet have involved more than 6,000 patients worldwide. In the 12 European countries where ACARIZAX® has been approved for HDM AR and AA, ACARIZAX® is indicated in adult patients (18-65 years) diagnosed by a clinical history and by a positive test for HDM sensitisation with at least one of the following conditions: Treating physicians should refer to full summary of product characteristics before considering ACARIZAX® for treatment in patients with house dust mite allergic asthma.3) About GINA4) GINA was launched in 1993 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and the World Health Organization. GINA’s programme is determined and its strategies for asthma care are shaped by committees made up of leading asthma experts from around the world. The GINA Scientific Committee prepares updates to their reports and guidelines each year, which are made available on the GINA Website as they are completed. The Scientific Committee has developed a sophisticated set of procedures to review the world’s literature with regards to asthma management and to update the GINA documents to reflect this state-of-the-art information.


ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a widely recognised practical resource developed to guide healthcare professionals and policy makers, and represents the latest clinical evidence and medical practice for the treatment and management of asthma. The strategy is updated annually based on review of recent scientific literature by an international panel of experts on the GINA Science Committee. The 2017 update, which includes new information regarding the use of allergy immunotherapy, has just been released and features the following addition to steps 3 and 4 of GINA's recommended stepwise treatment of asthma in adult house dust mite (HDM) sensitive patients: Consider adding SLIT (sublingual allergy immunotherapy) in adult HDM sensitive patients with allergic rhinitis who have exacerbations despite ICS (inhaled corticosteroids), provided FEV is > 70% of predicted lung function.[1] This change draws upon recently published results from ALK's Phase III clinical trial evaluating the treatment of HDM allergic asthma with the HDM SLIT-tablet, ACARIZAX® in The Journal of the American Medical Association (JAMA) [2] Henrik Jacobi, Executive Vice President of Research & Development at ALK, said: "We are extremely pleased to see the recognition of ACARIZAX® clinical evidence in the management of asthma. This confirms our long-held conviction that allergy immunotherapy has an important role to play in the treatment of allergic asthma, a belief confirmed by the unprecedented clinical development programme for ACARIZAX®, currently the only HDM SLIT-tablet indicated for use in patients with house dust mite allergic asthma that is not well controlled." House dust mite allergy and asthma often coexist. More than half of asthmatic patients have been reported to have house dust mite sensitisation. He continued: "ALK is committed to gathering further evidence to support the wider recognition of allergy immunotherapy as a treatment option for asthma, and to investigating the potential role for allergy immunotherapy in preventing the onset of asthma." Professor J. Christian Virchow, of the University of Rostock and lead author of the recently published paper in JAMA says: "This is very encouraging. I am pleased to see findings from this important trial translated into clinical guidelines. This underlines the importance of performing robust evidence based trials in allergy immunotherapy." ACARIZAX® is currently approved for the treatment in HDM allergic asthma in 12 European countries and Australia. ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy - a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at http://www.alk.net. House dust mites (HDM) are the most common cause of allergy in the world. HDM allergy is estimated to affect around 90 million people in Europe, North America and Japan, and more than 100 million in China. It is estimated that one in 10 adults with allergic rhinitis are poorly controlled with current standard therapies. The condition appears early in life, is present all year round and patients face an elevated risk of developing asthma and other allergies. For some of these patients, the HDM SLIT-tablet is a relevant treatment option which can improve their quality of life and potentially modify the underlying cause of their disease. ALK's HDM SLIT-tablet is a treatment for house dust mite-induced allergic rhinitis (AR) with or without conjunctivitis and allergic asthma (AA) that is not well controlled by symptomatic medication. In Europe, where it is marketed as ACARIZAX®, the product has been approved in 14 countries for the treatment of AR, 12 of which also include the HDM AA indication. It is also approved in Japan for AR, where it is licensed by ALK to Torii and marketed under the trade name MITICURE[TM] and in Australia for HDM AR and AA, where it is licensed by ALK to Seqirus. The product is also being developed for a number of other markets around the world, including China, North America and countries in Southeast Asia. Altogether, clinical development activities for the HDM SLIT-tablet have involved more than 6,000 patients worldwide. In the 12 European countries where ACARIZAX® has been approved for HDM AR and AA, ACARIZAX® is indicated in adult patients (18-65 years) diagnosed by a clinical history and by a positive test for HDM sensitisation with at least one of the following conditions: Treating physicians should refer to full summary of product characteristics before considering ACARIZAX® for treatment in patients with house dust mite allergic asthma.[3] GINA was launched in 1993 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and the World Health Organization. GINA's programme is determined and its strategies for asthma care are shaped by committees made up of leading asthma experts from around the world. The GINA Scientific Committee prepares updates to their reports and guidelines each year, which are made available on the GINA Website as they are completed. The Scientific Committee has developed a sophisticated set of procedures to review the world's literature with regards to asthma management and to update the GINA documents to reflect this state-of-the-art information.


HORSHOLM, Denmark, Feb. 28, 2017 /PRNewswire/ -- ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF) today announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a widely recognised practical resource developed to guide healthcare professionals and policy makers, and represents the latest clinical evidence and medical practice for the treatment and management of asthma. The strategy is updated annually based on review of recent scientific literature by an international panel of experts on the GINA Science Committee. The 2017 update, which includes new information regarding the use of allergy immunotherapy, has just been released and features the following addition to steps 3 and 4 of GINA's recommended stepwise treatment of asthma in adult house dust mite (HDM) sensitive patients: Consider adding SLIT (sublingual allergy immunotherapy) in adult HDM sensitive patients with allergic rhinitis who have exacerbations despite ICS (inhaled corticosteroids), provided FEV is > 70% of predicted lung function.[1] This change draws upon recently published results from ALK's Phase III clinical trial evaluating the treatment of HDM allergic asthma with the HDM SLIT-tablet, ACARIZAX® in The Journal of the American Medical Association (JAMA) [2] Henrik Jacobi, Executive Vice President of Research & Development at ALK, said: "We are extremely pleased to see the recognition of ACARIZAX® clinical evidence in the management of asthma. This confirms our long-held conviction that allergy immunotherapy has an important role to play in the treatment of allergic asthma, a belief confirmed by the unprecedented clinical development programme for ACARIZAX®, currently the only HDM SLIT-tablet indicated for use in patients with house dust mite allergic asthma that is not well controlled." House dust mite allergy and asthma often coexist. More than half of asthmatic patients have been reported to have house dust mite sensitisation. He continued: "ALK is committed to gathering further evidence to support the wider recognition of allergy immunotherapy as a treatment option for asthma, and to investigating the potential role for allergy immunotherapy in preventing the onset of asthma." Professor J. Christian Virchow, of the University of Rostock and lead author of the recently published paper in JAMA says: "This is very encouraging. I am pleased to see findings from this important trial translated into clinical guidelines. This underlines the importance of performing robust evidence based trials in allergy immunotherapy." ACARIZAX® is currently approved for the treatment in HDM allergic asthma in 12 European countries and Australia. ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy - a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at http://www.alk.net. House dust mites (HDM) are the most common cause of allergy in the world. HDM allergy is estimated to affect around 90 million people in Europe, North America and Japan, and more than 100 million in China. It is estimated that one in 10 adults with allergic rhinitis are poorly controlled with current standard therapies. The condition appears early in life, is present all year round and patients face an elevated risk of developing asthma and other allergies. For some of these patients, the HDM SLIT-tablet is a relevant treatment option which can improve their quality of life and potentially modify the underlying cause of their disease. ALK's HDM SLIT-tablet is a treatment for house dust mite-induced allergic rhinitis (AR) with or without conjunctivitis and allergic asthma (AA) that is not well controlled by symptomatic medication. In Europe, where it is marketed as ACARIZAX®, the product has been approved in 14 countries for the treatment of AR, 12 of which also include the HDM AA indication. It is also approved in Japan for AR, where it is licensed by ALK to Torii and marketed under the trade name MITICURE[TM] and in Australia for HDM AR and AA, where it is licensed by ALK to Seqirus. The product is also being developed for a number of other markets around the world, including China, North America and countries in Southeast Asia. Altogether, clinical development activities for the HDM SLIT-tablet have involved more than 6,000 patients worldwide. In the 12 European countries where ACARIZAX® has been approved for HDM AR and AA, ACARIZAX® is indicated in adult patients (18-65 years) diagnosed by a clinical history and by a positive test for HDM sensitisation with at least one of the following conditions: Treating physicians should refer to full summary of product characteristics before considering ACARIZAX® for treatment in patients with house dust mite allergic asthma.[3] GINA was launched in 1993 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and the World Health Organization. GINA's programme is determined and its strategies for asthma care are shaped by committees made up of leading asthma experts from around the world. The GINA Scientific Committee prepares updates to their reports and guidelines each year, which are made available on the GINA Website as they are completed. The Scientific Committee has developed a sophisticated set of procedures to review the world's literature with regards to asthma management and to update the GINA documents to reflect this state-of-the-art information.


News Article | February 22, 2017
Site: www.PR.com

SMi’s Paediatric Clinical Trials show returns to London for the 11th year on 20th-21st March 2017. London, United Kingdom, February 22, 2017 --( Through a series of interactive conference sessions, presentations and a workshop led by industry experts; the 2017 agenda will discuss current clinical trials, implementation, drug development, recruitment and retention, ethical issues and regulations. Key presentations not to be missed: - Bianca McDade, Director Regulatory Affairs, GSK - Tom Willgoss, Senior Outcomes Research Scientist, Patient-Centred Outcomes Research, Roche - Karl-Heinz Huemer, Scientific Committee Member and Expert, EMA, PDCO - Hernando Patino, Paediatric Drug Development Lead, Johnson & Johnson - Deborah Lee, VP Clinical Development, Insys Therapeutics - Andy Kenwright, Senior Statistical Scientist, Roche - Robert Kahn, Former Senior Safety Science Leader, Global Pediatric Oncology, Genentech Highlights for 2017: - Update from the EMA on the PDCO's 10 year review into paediatric investigation plans - Discuss clinical trial legislation in the EU and US - Review challenges in paediatric drug development for rare diseases - Optimise approaches to paediatric drug formulation to improve clinical success - Evaluate recruitment and retention - Discuss hot topic of data extrapolation In the lead up to the event SMi have released some pre-conference interviews with some of the speakers. For further insight into the topics being discussed at this year’s conference and an overall look into the paediatric trials field visit the download centre of the event website to access the 2017 speaker interview series. Interviews available to download include: Roche, Insys Therapeutics, Paediatric Research Consultancy, The Birmingham Children’s Hospital and Klausrose Consulting. Countries attending Paediatric Clinical Trials 2017 include: Australia, Austria, Belgium, Denmark, France, Germany, Netherlands, Spain, Switzerland, United Kingdom & USA. For those who are interested in attending register online at the event website www.paediatric-trials.co.uk/prcom Paediatric Clinical Trials 20-21 March 2017 Copthorne Tara Hotel, London, UK www.paediatric-trials.co.uk/prcom Sponsorship enquiries: Contact Alia Malick on: +44 (0) 20 7827 6168 or email amalick@smi-online.co.uk Group bookings: Contact Ameenah Begum on: +44 (0) 20 7827 6166 or email abegum@smi-online.co.uk About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, February 22, 2017 --( PR.com )-- With just 4 weeks to go, registration will be closing soon for SMi’s Paediatric Clinical Trials 2017. The event will bring together Clinical Operations Leads and Heads of Clinical Trials to review the developments leading to the advancement of paediatric medicines.Through a series of interactive conference sessions, presentations and a workshop led by industry experts; the 2017 agenda will discuss current clinical trials, implementation, drug development, recruitment and retention, ethical issues and regulations.Key presentations not to be missed:- Bianca McDade, Director Regulatory Affairs, GSK- Tom Willgoss, Senior Outcomes Research Scientist, Patient-Centred Outcomes Research, Roche- Karl-Heinz Huemer, Scientific Committee Member and Expert, EMA, PDCO- Hernando Patino, Paediatric Drug Development Lead, Johnson & Johnson- Deborah Lee, VP Clinical Development, Insys Therapeutics- Andy Kenwright, Senior Statistical Scientist, Roche- Robert Kahn, Former Senior Safety Science Leader, Global Pediatric Oncology, GenentechHighlights for 2017:- Update from the EMA on the PDCO's 10 year review into paediatric investigation plans- Discuss clinical trial legislation in the EU and US- Review challenges in paediatric drug development for rare diseases- Optimise approaches to paediatric drug formulation to improve clinical success- Evaluate recruitment and retention- Discuss hot topic of data extrapolationIn the lead up to the event SMi have released some pre-conference interviews with some of the speakers. For further insight into the topics being discussed at this year’s conference and an overall look into the paediatric trials field visit the download centre of the event website to access the 2017 speaker interview series. Interviews available to download include: Roche, Insys Therapeutics, Paediatric Research Consultancy, The Birmingham Children’s Hospital and Klausrose Consulting.Countries attending Paediatric Clinical Trials 2017 include: Australia, Austria, Belgium, Denmark, France, Germany, Netherlands, Spain, Switzerland, United Kingdom & USA. For those who are interested in attending register online at the event website www.paediatric-trials.co.uk/prcomPaediatric Clinical Trials20-21 March 2017Copthorne Tara Hotel, London, UKwww.paediatric-trials.co.uk/prcomSponsorship enquiries: Contact Alia Malick on: +44 (0) 20 7827 6168 or email amalick@smi-online.co.ukGroup bookings: Contact Ameenah Begum on: +44 (0) 20 7827 6166 or email abegum@smi-online.co.ukAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


News Article | February 27, 2017
Site: globenewswire.com

Copenhagen, Denmark; February 27, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) summons the Annual General Meeting on Tuesday, March 28, 2017 at 2:00 PM CEST at the Tivoli Hotel & Congress Center, Arni Magnussons Gade 2-4, DK-1577 Copenhagen V, Denmark. 1. Report by the Board of Directors on the Company’s activities during the past year. 2. Presentation and adoption of the audited Annual Report 2016 and resolution to discharge the Board of Directors and the Executive Management from liability. 3. Resolution on the distribution of profits as recorded in the adopted Annual Report. 4. Election of members of the Board of Directors. 6. Proposals from the Board of Directors: (a) Amendment of the general guidelines for incentive-based remuneration of the Board of Directors and the Executive Management. (b) Approval of remuneration to the Board of Directors for 2017. (c) Amendment of Article 5 of the Company's Articles of Association on authorization to issue warrants. (d) Insertion of a new Article 17 in the Company's Articles of Association on language of company announcements. 7. Authorization of the chairman of the General Meeting. It is proposed to take note of the report of the Board of Directors. It is proposed to adopt the audited Annual Report and to grant discharge to the Board of Directors and the Executive Management. It is proposed that the profit of DKK 1,331 million for the accounting year 2016 be carried forward by transfer to the accumulated deficit. Pursuant to Article 12 of the Company’s Articles of Association, the members of the Board of Directors are elected for periods of one year. The election period for Mats Pettersson, Dr. Anders Gersel Pedersen, Pernille Erenbjerg, Dr. Burton G. Malkiel and Dr. Paolo Paoletti expires at this General Meeting. The Board of Directors proposes to re-elect Mats Pettersson, Dr. Anders Gersel Pedersen, Pernille Erenbjerg and Dr. Paolo Paoletti for a one-year period. Dr. Burton G. Malkiel does not stand for re-election. The Board of Directors further proposes that Rolf Hoffman and Deirdre P. Connelly are elected as new members of the Board of Directors for a one year period so that the Board of Directors is composed of six members elected by the General Meeting. About Mats Pettersson, B.Sc. Swedish, 71, Male Board Chairman (Independent, elected by the General Meeting); Chairman of the Nominating and Corporate Governance Committee and member of the Audit Committee and the Compensation Committee. First elected 2013, current term expires 2017. Special Competences Extensive experience from international research-based biotech and pharmaceutical companies. Founder and CEO of SOBI AB. Responsible for several transforming Business Development deals and member of various executive management committees at Pharmacia. Current Board Positions Member: Magle Chemoswed AB. About Anders Gersel Pedersen, M.D., Ph.D. Danish, 65, Male Deputy Chairman (Non-independent, elected by the General Meeting); Chairman of the Compensation Committee and member of the Nominating and Corporate Governance Committee. First elected 2003, current term expires 2017. Special Competences Business and management experience in the pharmaceutical industry, including expertise in clinical research, development, regulatory affairs and product life cycle management. Current Position, Including Managerial Positions Executive Vice President, Research & Development at H. Lundbeck A/S. Current Board Positions Member: ALK-Abelló A/S. Deputy Chairman: Bavarian Nordic A/S. About Pernille Erenbjerg Danish, 49, Female Board member (Independent, elected by the General Meeting); Chairman of the Audit Committee and member of the Nominating and Corporate Governance Committee. First elected 2015, current term expires 2017. Special Competences Senior executive management and broad business experience from the telecoms industry. Comprehensive all round background within finance including extensive exposure to stock markets, equity and debt investors. Certified Public Accountant background. Responsible for major transformation processes in complex organizations including M&A. Current Position, Including Managerial Positions Group CEO and President of TDC A/S. Current Board Positions Member: DFDS A/S. Audit Committee Chairman: DFDS A/S. About Paolo Paoletti, M.D. Italian (USA citizenship), 66, Male Board member (Independent, elected by the General Meeting); Member of the Compensation Committee. First elected 2015, current term expires 2017. Special Competences Extensive experience in research, development and commercialization in the pharmaceutical industry. Successfully conducted submissions and approvals of new cancer drugs and new indications in the USA and in Europe. Responsible for seven new medicines for cancer patients during his 10 years at GlaxoSmithKline and one new cancer medicine during his time at Eli Lilly. Current Position, Including Managerial Positions Acting CEO at GammaDelta Therapeutics. Current Board Positions Chairman: PsiOxus Therapeutics Limited. Member: FORMA Therapeutics, Inc. and NuCana BioMed Limited. About Rolf Hoffmann German, 57, Male Independent Special Competencies Extensive international management experience with expertise in creating and optimizing commercial opportunities in global markets. Additional expertise in P&L management, governance and corporate integrity agreement management, compliance and organizational efficiency. Over 20 years’ experience in the international pharmaceutical and biotechnology industries at Eli Lilly and Company and Amgen, Inc. Current Position, including Managerial Positions Adjunct Professor of Strategy and Entrepreneurship at the University of North Carolina Business School. Current Board Positions: Member: STADA Arzneimittel AG and Trigemina, Inc. About Deirdre P. Connelly American, 55, Female Independent Special Competencies More than 30 years’ experience as a corporate leader and extensive experience in corporate governance as a board member. Comprehensive experience with business turnaround, corporate culture transformation, product launch, and talent development. Successfully directed the launch of more than 20 new pharmaceutical drugs. Former President, North America Pharmaceuticals for GlaxoSmithKline. Current Board Positions: Member: Macy’s Inc. and Lincoln National Corporation. If Deirdre P. Connelly is elected by the General Meeting, the Company’s goal of increasing the proportion of female directors to at least 25% of the directors elected by the General Meeting will be met. The Board of Directors proposes re-election of PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab as the Company’s elected auditor in accordance with the Audit Committee's recommendation. The Audit Committee has not been influenced by third parties and has not been subject to any agreement with third parties, which limits the General Meeting’s choice to certain auditors or audit firms. The Board of Directors proposes to amend the Company's general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management to specify that a new member of the Executive Management may receive a sign-on payment upon engagement subject to certain claw-back provisions. It is further proposed that, in exceptional cases, international, and in particular US based, members of the Executive Management, on an annual basis may be granted restricted stock units and/or warrants corresponding to a value (at the time of grant) of up to four (4) times the member's annual base salary, calculated before any pension contribution and bonus payment, in the year of grant. The value (at the time of grant) of the annual grant may, however, not exceed DKK 25 million. The motivation behind the proposed amendment is to ensure that a competitive compensation package can be offered to future, and in particular US based, members of the Executive Management. It is the Company’s belief that it is important for the Company’s continued success that the Company in the future will be able to attract and retain members of the Executive Management from an international pool. It is moreover proposed to amend the general guidelines so that members of the Executive Management may be granted restricted stock units or a combination of restricted stock units and warrants. If members of the executive management are granted a combination of restricted stock units and warrants, the proportional value of the warrants may not exceed 50% of the total value (at the time of grant). It is further proposed to amend the general guidelines so that restricted stock units granted to a new member of the Board of Directors upon election may no longer exceed a value (at the time of grant) of four (4) times the fixed annual base fee. As a result hereof, the maximum value (at the time of grant) of restricted stock units that may be granted to members of the Board of Directors upon election will correspond to up to four (4) times the fixed annual base fee. It is moreover proposed that the proportional value (at the time of grant) of the restricted stock units that a member of the Board of Directors may be granted on an annual basis is lowered. As a result hereof, the maximum value (in DKK) of restricted stock units that may be granted to members of the Board of Directors on an annual basis will be lowered notwithstanding the increase in the basic fee for members of the Board of Directors proposed under item 6(b). Furthermore, it is proposed that the general guidelines are amended so that vesting of restricted stock units and warrants granted to members of the Executive Management may be subject to fulfilment of forward-looking performance criteria as determined by the Board of Directors. Vesting of restricted stock units granted to members of the Board of Directors shall, however, not be subject to forward-looking performance criteria. It is further proposed to amend the general guidelines so that warrants granted to members of the Executive Management vest three years after the date of the grant in accordance with the corporate governance recommendations. The Board of Directors will implement this through a subsequent general amendment of the Company's warrant program so that all warrants granted after the adoption of this proposal will vest three years after the grant date. The general guidelines have furthermore been subject to a general update and editorial changes with a view to make the general guidelines more reader-friendly. Going forward, the Company's general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management will be included in the Company’s Remuneration Principles. The Board of Directors proposes that the basic fee for members of the Board of Directors is increased from DKK 375,000 to DKK 400,000, and that the deputy chairman receives two times the increased basic fee and that the chairman receives three times the increased basic fee. It is further proposed that the supplemental fee for membership of the board committees is increased from up to DKK 75,000 per membership to up to DKK 100,000 per membership, and that a committee chairman receives up to DKK 150,000. It is moreover proposed that the fee per committee meeting is increased from DKK 9,000 per committee meeting to DKK 10,000 per committee meeting. The Board of Directors plans to establish a Scientific Committee where the remuneration will be within the range of the proposed committee fees. Members of the Board of Directors will furthermore receive share-based instruments in the form of restricted stock units within the scope described and adopted in the Company’s general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management. Re item 6 (c) on the agenda: The Board of Directors proposes that Article 5 of the Company's Articles of Association be amended so that the Board of Directors is authorised to issue an additional 500,000 warrants entitling the holder to subscribe for the Company's shares up to a nominal value of DKK 500,000. With this authorization to issue an additional 500,000 warrants, the potential dilution (including the outstanding warrants and the aggregate unused part of the existing authorization) is kept below 5% of the share capital. It is further proposed to amend Article 5 so that the Board of Directors is no longer entitled to issue warrants to members of the Board of Directors and consultants of the Company and its subsidiaries. This amendment will align the wording in Article 5 with the Company’s general guidelines for incentive-based remuneration for the Board of Directors and the Executive Management according to which members of the Board of Directors may only be granted restricted stock units. It is moreover proposed to amend Article 5 to specify that the Board of Directors’ authorizations entitle the Board of Directors to issue warrants to, among others, employees employed in the Company's directly and indirectly owned subsidiaries. This change is a result of Genmab B.V. having become a wholly-owned subsidiary of Genmab Holding B.V. The proposal means that Article 5 will read as follows: By decision of the General Meeting on April 25, 2012 the Board of Directors is authorized to issue on one or more occasions warrants to subscribe the Company’s shares up to a nominal value of DKK 250,000 and to make the related capital increases in cash up to a nominal value of DKK 250,000. The Board of Directors has issued 250,000 warrants and reissued 42,375 warrants under this authorization. This authorization shall remain in force for a period ending on April 25, 2017. Further, by decision of the General Meeting on April 17, 2013 the Board of Directors is authorized to issue on one or more occasions additional warrants to subscribe the Company’s shares up to a nominal value of DKK 600,000 and to make the related capital increases in cash up to a nominal value of DKK 600,000. The Board of Directors has issued 600,000 warrants and reissued 15,250 warrants under this authorization. This authorization shall remain in force for a period ending on April 17, 2018. Moreover, by decision of the General Meeting on April 9, 2014 the Board of Directors is authorized to issue on one or more occasions additional warrants to subscribe the Company’s shares up to a nominal value of DKK 500,000 and to make the related capital increases in cash up to a nominal value of DKK 500,000. The Board of Directors has issued 406,166 warrants and reissued 4,775 warrants under this authorization. This authorization shall remain in force for a period ending on April 9, 2019. Moreover, by decision of the General Meeting on March 28, 2017 the Board of Directors is authorized to issue on one or more occasions additional warrants to subscribe the Company’s shares up to a nominal value of DKK 500,000 and to make the related capital increases in cash up to a nominal value of DKK 500,000. This authorization shall remain in force for a period ending on March 28, 2022. The authorizations entitle the Board of Directors to issue warrants to the Company’s employees as well as employees of the Company’s directly and indirectly owned subsidiaries. Subject to the rules in force at any time, the Board of Directors may reuse or reissue lapsed non-exercised warrants, if any, provided that the reuse or reissue occurs under the same terms and within the time limitations set out in this authorization. Reuse is to be construed as the Board of Directors' entitlement to let another party enter into an existing agreement on warrants. Reissue is to be construed as the Board of Directors' option to reissue new warrants under the same authorization, if previously issued warrants have lapsed. The existing shareholders of the Company shall not have a right of pre-emption in connection with the issue of warrants based on these authorizations. One warrant shall give the right to subscribe one share with a nominal value of DKK 1 at a subscription price per share determined by the Board of Directors which, however, shall be no less than the market price per share of the Company’s shares at the time of issue. The exercise period for the issued warrants shall be determined by the Board of Directors. The Board of Directors is authorized to set out more detailed terms for the warrants that are to be issued based on these authorizations. The existing shareholders of the Company shall not have a right of pre-emption in connection with issue of shares on the basis of warrants. The shares that are issued through the exercise of warrants shall have the same rights as existing shares cf. these Articles of Association. The Board of Directors has exercised the above authorizations as stipulated in schedule A which is an integral part of these articles.” The Board of Directors proposes that a new Article 17 be inserted in the Articles of Association specifying that the Board of Directors may decide whether company announcements shall be prepared in English only. As a result, the present Articles 17, 18, 19 and 20 are renumbered to Articles 18, 19, 20 and 21. The new Article 17 will read as follows: Company announcements may be prepared in English only, if decided by the Board of Directors.” The Board of Directors proposes that the chairman of the General Meeting is authorized to register the resolutions passed by the General Meeting with the Danish Business Authority and to make such amendments and additions thereto or therein, including the Articles of Association of the Company, as the Danish Business Authority may require for registration. The proposals under item 6 (c) and 6 (d) of the agenda to amend the Articles of Association are required to be adopted by an affirmative vote of not less than 2/3 of the votes cast as well as of the voting share capital represented at the General Meeting. The Company's share capital amounts to DKK 60,350,056 divided into shares of DKK 1 each or any multiple hereof. Each share amount of DKK 1 shall entitle the shareholder to one vote. Pursuant to Section 99 of the Danish Companies Act, the following documents will be published on the Company’s website (www.genmab.com) no later than March 6, 2017: (1) the notice of the Annual General Meeting, (2) information on the total number of shares and votes issued by the Company on the date of the notice, (3) the agenda, (4) the complete proposals to be presented at the Annual General Meeting, (5) the Annual Report for 2016 and (6) forms needed to register for the Annual General Meeting and possible proxy voting and post voting. Registration Date: A shareholder’s right to participate in and vote at the Annual General Meeting is determined in proportion to the number of shares the shareholder owns on the registration date Tuesday March 21, 2017. Admission card: Admission cards may be requested no later than Friday March 24, 2017 by: Proxy vote: Shareholders who do not expect to be able to participate in the General Meeting may: Go to the Company’s website www.genmab.com or www.uk.vp.dk/agm to assign a proxy to the Board of Directors to vote in accordance with its recommendations, or assign a proxy indicating how you wish your votes to be cast by checking the boxes on the electronic proxy form. This must be done by 11:59 PM CET on Friday March 24, 2017. You may complete and sign the proxy form and return it by post to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark, or scan it and return it by e-mail to vpinvestor@vp.dk or by fax to +45 43 58 88 67 so that it is received by VP Investor Services A/S by 11:59 PM CET on Friday March 24, 2017. Postal vote: Shareholders who do not expect to be able to participate in the General Meeting may also vote by post: Go to the Company’s website www.genmab.com or www.uk.vp.dk/agm to vote by post. This must be done by 10:00 AM CEST on Monday March 27, 2017. You may complete and sign the postal voting form and return it by post to VP Investor Services A/S, Weidekampsgade 14, DK-2300 Copenhagen S, Denmark, or scan it and return it by e-mail to vpinvestor@vp.dk or by fax to +45 43 58 88 67 so that it is received by VP Investor Services A/S by 10:00 AM CEST on Monday March 27, 2017. Please note that you may either assign a proxy or vote by post, but not both. Any shareholder, to whom an admission card already has been issued, but who is prevented from attending the Annual General Meeting is kindly asked to notify the Company - preferably before Friday March 24, 2017. Right to ask questions: Prior to the General Meeting, the shareholders may ask the Company’s management in writing about matters of importance to the evaluation of the Annual Report 2016, the Company’s position or any of the other matters which are to be transacted at the General Meeting, or the Company’s relation to other companies in the Genmab Group. Shareholders’ questions must be sent by letter to Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications or by e-mail to r.gravesen@genmab.com. The question may be answered in writing by e.g. making the answer available on the Company’s website (www.genmab.com). The question may be neglected if the shareholder asking the question is not represented at the General Meeting. At the General Meeting, the shareholders may also ask the Company’s management about the above matters and may ask questions regarding the Annual Report 2016 to the auditor appointed by the General Meeting. About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com. Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.


News Article | February 15, 2017
Site: www.eurekalert.org

Scientists know a great deal about blue whales off California, where the endangered species has been studied for decades. But they know far less about blue whales in the Northern Indian Ocean, where ships strike and kill some of the largest animals on Earth. Now a research team has found a way to translate their knowledge of blue whales off California and in the eastern tropical Pacific Ocean to the other side of the world, revealing those areas of the Northern Indian Ocean where whales are likely to be encountered. The team of scientists from NOAA Fisheries and the Sri Lankan Blue Whale Project published the findings in the journal Diversity and Distributions. The Scientific Committee of the International Whaling Commission included the results of the study when assessing a shift in busy shipping lanes off the south coast of Sri Lanka that will reduce the danger to whales in an important feeding area. "Small changes in shipping routes can be a very effective way to address a serious conservation issue with minimal inconvenience to the shipping industry, but rely on a good understanding of the relationship between whale distribution and habitat," said Russell Leaper, a member of the Scientific Committee. "This study makes an important contribution towards that understanding." To meet requirements of the U.S. Marine Mammal Protection Act, NOAA Fisheries regularly conducts marine mammal and ecosystem assessment surveys. Surveys off the U.S. West Coast and in the eastern tropical Pacific have shown that the upwelling of deep ocean water rich in nutrients supports dense patches of krill that blue whales feed on. This information has proven critical in addressing the emerging problem of ships striking blue whales, and has informed the management of ship traffic to and from the busy ports of Los Angeles and Long Beach to mitigate this problem. "We are fortunate in the United States to have some of the best marine mammal data sets in the world," said Jessica Redfern, a research scientist at NOAA Fisheries Southwest Fisheries Science Center in La Jolla, Calif., and lead author of the new study. "It was exciting to explore how we could use these data sets to aid conservation efforts in parts of the world where few data exist." The research developed computer models of blue whale habitat off the U.S. West Coast and in the eastern tropical Pacific, including upwelling and underwater topography that affects areas of krill concentration. The models then identified similar upwelling and feeding regions in the Northern Indian Ocean that are also likely to be important habitat for the endangered species. "The Sri Lankan Blue Whale Project has spear-headed efforts to draw attention to and mitigate the risk of ships striking blue whales in Sri Lankan waters. To best protect this species in this data-limited region, it is essential to adapt approaches developed in other parts of the world. Our collaboration achieves just that," said Asha de Vos, founder of the Sri Lankan Blue Whale Project and a coauthor on the study. The Northern Indian Ocean and its inhabitants have not been surveyed to the same extent as the eastern Pacific Ocean, and much of the information about whale distributions comes from Soviet whaling several decades ago. However, the model results matched up well with the limited information available, the scientists reported. The model suggests that the distribution of blue whales in the Northern Indian Ocean may shift seasonally, following their food as monsoon climate patterns alter the most productive habitat. The scientists concluded that research and monitoring is critical in the areas identified as blue whale habitat in the Northern Indian Ocean because many of these areas overlap with some of the busiest shipping routes in the world. "Marine mammals face threats from human activities in most of the world's oceans, but we lack the data needed to address these threats in many areas," Redfern said. "The data collected aboard our surveys allow us to predict species habitat in other parts of the world. Understanding species habitat allows us to address conservation problems that are often unexpected and critical to maintaining healthy populations."

Loading Scientific Committee collaborators
Loading Scientific Committee collaborators